Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Nov 10 - Nov 15
Abnormal IGF-1 and GH levels have been proposed to play a key role in obesity [130, 240, 241]
Many athletes, military service members and patients using experimental therapies ask, do peptides show up on drug tests? BPC-157 (Body Protection Compound-157) is an investigational peptide studied for tissue repair
International Regulatory Landscape Healthcare Provider Considerations Healthcare providers who prescribe or recommend BPC-157 face potential: Disciplinary action from state medical boards Medical license implications (sanctions, restrictions, suspension) Malpractice liability (insurance often excludes experimental treatments) Federal regulatory enforcement Research and Access Legitimate research pathways: Investigational New Drug (IND) application required for human research Institutional Review Board (IRB) approval required GMP standards required for research-grade materials Current access: Research peptide suppliers (variable quality) Some compounding pharmacies (legal status varies) Clinical trials (limited availability) Why This Regulatory Status Exists BPC-157's prohibition stems from: Limited clinical data Only small pilot studies published (~28 human subjects total)
May relate to blood pressure effects
